SNAP-8

Unverified protocol notes

Protocol logic check

Independent evidence

Regulatory status: no approved label identified

Storage

No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.

Contraindications (limited evidence)

• Known hypersensitivity to SNAP-8 (acetyl octapeptide-3), methionine-containing peptides, or carrier vehicle excipients. Limited / unverified
• Active neuromuscular disease affecting facial muscles (myasthenia gravis, Lambert-Eaton syndrome, ALS): SNAP-8's inhibition of neuromuscular acetylcholine release in subjects with pre-existing neuromuscular junction dysfunction could compound existing muscle weakness. Limited / unverified
• Concurrent botulinum toxin injections in the same treatment area: SNAP-8's SNARE competitive inhibition is additive with Botulinum toxin's SNAP-25 cleavage; while the combination theoretically produces greater muscle relaxation, the combined neuromuscular blockade at the same anatomical sites has not been characterized for safety and could produce unexpected depth of paralysis. Limited / unverified
• Active dermatitis, eczema, or psoriasis in the application area: compromised barrier function increases peptide penetration and could produce enhanced neuromuscular effects beyond the intended level. Limited / unverified
• Open wounds or compromised skin in the application area. Limited / unverified
• Application near or in the eyes without ophthalmic safety evaluation: SNAP-25 is expressed in multiple neuronal populations beyond facial motor neurons; periocular application in quantities reaching the conjunctiva or anterior chamber without ophthalmic testing is inadvisable. Limited / unverified

Side effects (limited evidence)

• Mild skin irritation and erythema: less common than with Matrixyl; occasional in sensitive subjects with certain carrier vehicle formulations; typically related to penetration enhancer components (propylene glycol) rather than the peptide itself. Limited / unverified
• Mild tingling on application: transient; as the octapeptide penetrates the stratum corneum; not indicative of irritation. Limited / unverified
• Slight facial heaviness or reduced expressivity: in subjects applying high concentrations (8-10%) to multiple facial zones simultaneously, the partial neuromuscular inhibition can produce a subjective sensation of mild facial muscle heaviness; entirely reversible; resolves within hours if application is discontinued. Limited / unverified
• Contact dermatitis (rare): delayed hypersensitivity to peptide components; documented rarely; requires patch testing and permanent avoidance of the specific formulation. Limited / unverified
• No systemic adverse effects: topical application with intact skin barrier limits systemic absorption to levels far below any pharmacologically active concentration; SNAP-8 is among the safest compounds in the database from a systemic safety standpoint. Limited / unverified
• Tolerance with long-term continuous use (theoretical): the SNAP-25 competitive inhibition mechanism is reversible and receptor-mediated; theoretical tachyphylaxis from downregulation of SNAP-25 or neuromuscular junction adaptation with prolonged continuous high-concentration application has not been documented in clinical use but represents a mechanistic consideration for very long-term protocols. Limited / unverified

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

None listed.

Sources

• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding